Mucodel Pharma has announced that a PK study of its intranasal naloxone met its endpoints and showed that the formulation based on its Co-Gel technology delivered the dose of naloxone faster than both an intranasal spray and intramuscular injection.
in February 2017, the Mucodel filed a citizen petition with the FDA challenging the the safety of intranasal naloxone. The company is also developing a buccal naloxone formulation called Exonal.
Mucodel Founder and CEO Madhu Hariharan commented, “We are extremely pleased with the pilot clinical results for our Co-Gel intranasal naloxone. It is clear from the ongoing opioid crisis that faster ways of delivering naloxone are desperately needed. Speed to efficacious blood levels is crucial for patients in respiratory distress. Moreover, higher peak plasma naloxone concentrations are needed to combat overdose associated with particularly powerful opioids.”
Read the Mucodel press release.
